IT201700106405A1 - Formulation for administration of SUMO2 - Google Patents

Formulation for administration of SUMO2

Info

Publication number
IT201700106405A1
IT201700106405A1 IT102017000106405A IT201700106405A IT201700106405A1 IT 201700106405 A1 IT201700106405 A1 IT 201700106405A1 IT 102017000106405 A IT102017000106405 A IT 102017000106405A IT 201700106405 A IT201700106405 A IT 201700106405A IT 201700106405 A1 IT201700106405 A1 IT 201700106405A1
Authority
IT
Italy
Prior art keywords
sumo2
formulation
administration
Prior art date
Application number
IT102017000106405A
Other languages
Italian (it)
Inventor
Luca Colnaghi
Luana Fioriti
Amir Levine
Original Assignee
Plico Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plico Biotech Inc filed Critical Plico Biotech Inc
Priority to IT102017000106405A priority Critical patent/IT201700106405A1/en
Priority to PCT/IB2018/057297 priority patent/WO2019058318A1/en
Publication of IT201700106405A1 publication Critical patent/IT201700106405A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IT102017000106405A 2017-09-22 2017-09-22 Formulation for administration of SUMO2 IT201700106405A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102017000106405A IT201700106405A1 (en) 2017-09-22 2017-09-22 Formulation for administration of SUMO2
PCT/IB2018/057297 WO2019058318A1 (en) 2017-09-22 2018-09-21 Formulations to administer SUMO2/3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000106405A IT201700106405A1 (en) 2017-09-22 2017-09-22 Formulation for administration of SUMO2

Publications (1)

Publication Number Publication Date
IT201700106405A1 true IT201700106405A1 (en) 2019-03-22

Family

ID=61024885

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000106405A IT201700106405A1 (en) 2017-09-22 2017-09-22 Formulation for administration of SUMO2

Country Status (2)

Country Link
IT (1) IT201700106405A1 (en)
WO (1) WO2019058318A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024192296A1 (en) * 2023-03-14 2024-09-19 Teh Trustees Of Columbia University In The City Of New York Compositions and methods for treating alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159782A1 (en) * 2011-05-24 2012-11-29 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High affinity sumo traps
US20130017554A1 (en) * 2011-06-23 2013-01-17 College Of William And Mary Sumo-specific affinity tag

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036268A2 (en) * 2012-08-29 2014-03-06 Mount Sinai School Of Medicine Indole derivatives as sumo activators
ITUA20161992A1 (en) * 2016-03-24 2017-09-24 Plico Biotech Inc SUMO AND ITS USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159782A1 (en) * 2011-05-24 2012-11-29 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High affinity sumo traps
US20130017554A1 (en) * 2011-06-23 2013-01-17 College Of William And Mary Sumo-specific affinity tag

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE LINDA ET AL: "SUMO and Alzheimer's Dis", NEUROMOLECULAR MEDICINE, HUMANA PRESS, US, vol. 15, no. 4, 25 August 2013 (2013-08-25), pages 720 - 736, XP035359268, ISSN: 1535-1084, [retrieved on 20130825], DOI: 10.1007/S12017-013-8257-7 *
PETRANKA KRUMOVA ET AL: "Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation", THE JOURNAL OF CELL BIOLOGY : JCB, vol. 88, no. 1, 11 July 2011 (2011-07-11), US, pages 494 - 60, XP055321408, ISSN: 0021-9525, DOI: 10.1083/jcb.201010117 *

Also Published As

Publication number Publication date
WO2019058318A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
DK3529248T3 (en) Pharmaceutical compositions
DK3386541T3 (en) Aqueous PHARMACEUTICAL FORMULATION INCLUDING ANTI-PD-1 ANTIBODY AVELUMAB
DK3236943T3 (en) COMPOSITIONS FOR ILEO-JEJUNAL DRUG ADMINISTRATION
DK3479819T5 (en) STABLE LIQUID PHARMACEUTICAL PREPARATION
DK3378482T3 (en) FORMULATION FOR ADMINISTRATION OF ANTI-TUMOR DRUG
DK3634377T3 (en) Pharmaceutical formulation
BR112016021012A2 (en) pharmaceutical compositions of therapeutically active compounds.
DK3529240T3 (en) Pharmaceutical compounds
DK3532029T3 (en) Liquid pharmaceutical composition
MA54716A (en) REDUCTION OF THE VISCOSITY OF PHARMACEUTICAL FORMULATIONS
MA43705A (en) PHARMACEUTICAL FORMULATION
DK3544584T3 (en) PHARMACEUTICAL PARENTERAL FORMULATION CONTAINING CARGLUMIC ACID
FR3039396B1 (en) BASE OF CONCENTRATED COSMETIC FORMULATION
FI20145117A (en) Stabilized adhesive formulation
DK3280447T3 (en) PHARMACEUTICAL FORMULATIONS
DK3601277T3 (en) PHARMACEUTICAL FORMULATION
DK3463365T3 (en) Pharmaceutical antifungal formulation
FI20145118A (en) Stabilized adhesive formulation
DK3173071T3 (en) FORMULATION OF MAROPITANT
DK3247394T3 (en) PHARMACEUTICAL FORMULATION INCLUDING ANTI-EGFR ANTIBODY
DK3256138T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM
IT201700038005A1 (en) Device for the administration of substances
MA43166A (en) FORMULATION OF FVIII
IT201700106405A1 (en) Formulation for administration of SUMO2
DK3324736T3 (en) New spot-on active ingredient formulation